View ValuationSquare Pharmaceuticals 将来の成長Future 基準チェック /16Square Pharmaceuticals利益と収益がそれぞれ年間11.4%と10.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.2% 11.4%なると予測されています。主要情報11.4%収益成長率11.40%EPS成長率Pharmaceuticals 収益成長14.8%収益成長率10.1%将来の株主資本利益率18.23%アナリストカバレッジLow最終更新日30 Apr 2026今後の成長に関する最新情報Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Female Independent Director Nasrin Akter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Square Pharmaceuticals PLC. to Report Q3, 2026 Results on Apr 29, 2026Square Pharmaceuticals PLC. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 25Square Pharmaceuticals PLC. to Report Q2, 2026 Results on Jan 29, 2026Square Pharmaceuticals PLC. announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 07Square Pharmaceuticals PLC. to Report Q1, 2026 Results on Nov 12, 2025Square Pharmaceuticals PLC. announced that they will report Q1, 2026 results on Nov 12, 2025お知らせ • Oct 24Square Pharmaceuticals plc announces Annual dividend, payable on January 14, 2026Square Pharmaceuticals plc announced Annual dividend of BDT 12.0000 per share payable on January 14, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.お知らせ • Oct 23Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025, at 10:00 Central Asia Standard Time.お知らせ • Apr 23Square Pharmaceuticals PLC. to Report Q3, 2025 Results on Apr 29, 2025Square Pharmaceuticals PLC. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 27Square Pharmaceuticals PLC. to Report Q2, 2025 Results on Jan 30, 2025Square Pharmaceuticals PLC. announced that they will report Q2, 2025 results on Jan 30, 2025Upcoming Dividend • Nov 17Upcoming dividend of ৳11.00 per shareEligible shareholders must have bought the stock before 24 November 2024. Payment date: 19 January 2025. Payout ratio is a comfortable 46% and the cash payout ratio is 94%. Trailing yield: 4.9%. Within top quartile of Bangladeshi dividend payers (4.3%). Higher than average of industry peers (3.6%).New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Dividend is not well covered by cash flows (94% cash payout ratio).お知らせ • Nov 08Square Pharmaceuticals PLC. to Report Q1, 2025 Results on Nov 14, 2024Square Pharmaceuticals PLC. announced that they will report Q1, 2025 results on Nov 14, 2024Declared Dividend • Oct 26Dividend of ৳11.00 announcedShareholders will receive a dividend of ৳11.00. Ex-date: 24th November 2024 Payment date: 19th January 2025 Dividend yield will be 5.1%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but not adequately covered by cash flows (90.0% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 46% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Oct 24+ 1 more updateSquare Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024Square Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024, at 10:00 Central Asia Standard Time.お知らせ • Oct 15Square Pharmaceuticals PLC. to Report Fiscal Year 2024 Results on Oct 23, 2024Square Pharmaceuticals PLC. announced that they will report fiscal year 2024 results on Oct 23, 2024Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳5.55 (vs ৳4.83 in 3Q 2023)Third quarter 2024 results: EPS: ৳5.55 (up from ৳4.83 in 3Q 2023). Revenue: ৳17.2b (up 8.4% from 3Q 2023). Net income: ৳4.92b (up 15% from 3Q 2023). Profit margin: 29% (up from 27% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Apr 26Square Pharmaceuticals PLC. to Report Q3, 2024 Results on Apr 29, 2024Square Pharmaceuticals PLC. announced that they will report Q3, 2024 results on Apr 29, 2024Reported Earnings • Feb 02Second quarter 2024 earnings released: EPS: ৳5.92 (vs ৳5.78 in 2Q 2023)Second quarter 2024 results: EPS: ৳5.92 (up from ৳5.78 in 2Q 2023). Revenue: ৳18.5b (up 14% from 2Q 2023). Net income: ৳5.24b (up 2.3% from 2Q 2023). Profit margin: 28% (down from 32% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Jan 26Square Pharmaceuticals PLC. to Report Q2, 2024 Results on Jan 31, 2024Square Pharmaceuticals PLC. announced that they will report Q2, 2024 results on Jan 31, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 4 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Nov 12Upcoming dividend of ৳10.50 per share at 5.0% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 47% but the company is paying out more than the cash it is generating. Trailing yield: 5.0%. Within top quartile of Bangladeshi dividend payers (3.3%). Higher than average of industry peers (2.5%).お知らせ • Oct 26Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Square Pharmaceuticals PLC. has recommended 105% Cash Dividend for the year ended June 30, 2023.お知らせ • Oct 24Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023, at 10:00 Bangladesh Standard Time. Agenda: To consider 105% Cash Dividend for the year ended June 30, 2023.お知らせ • Oct 13Square Pharmaceuticals PLC. to Report Fiscal Year 2023 Results on Oct 22, 2023Square Pharmaceuticals PLC. announced that they will report fiscal year 2023 results on Oct 22, 2023Reported Earnings • May 04Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.Reported Earnings • Feb 01Second quarter 2023 earnings released: EPS: ৳5.78 (vs ৳5.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳5.78 (up from ৳5.24 in 2Q 2022). Revenue: ৳16.2b (up 14% from 2Q 2022). Net income: ৳5.13b (up 10% from 2Q 2022). Profit margin: 32% (down from 33% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Nov 22Upcoming dividend of ৳10.00 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 23 January 2023. Payout ratio is a comfortable 29% and the cash payout ratio is 76%. Trailing yield: 4.8%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.6%).Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ৳5.15 (vs ৳4.36 in 3Q 2021)Third quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 4 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.Reported Earnings • May 02Third quarter 2022 earnings: EPS exceeds analyst expectationsThird quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.Reported Earnings • Feb 03Second quarter 2022 earnings: EPS exceeds analyst expectationsSecond quarter 2022 results: EPS: ৳5.24 (up from ৳4.33 in 2Q 2021). Revenue: ৳14.2b (up 15% from 2Q 2021). Net income: ৳4.64b (up 21% from 2Q 2021). Profit margin: 33% (up from 31% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).Reported Earnings • May 09Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.Reported Earnings • Feb 01Second quarter 2021 earnings released: EPS ৳4.33 (vs ৳3.98 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳12.4b (up 11% from 2Q 2020). Net income: ৳3.84b (up 8.7% from 2Q 2020). Profit margin: 31% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 14New 90-day high: ৳238The company is up 22% from its price of ৳195 on 15 October 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳119 per share.Is New 90 Day High Low • Dec 21New 90-day high: ৳203The company is up 4.0% from its price of ৳196 on 22 September 2020. The Bangladeshi market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳150 per share.Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ৳4.28The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳12.1b (up 11% from 3Q 2019). Net income: ৳3.62b (up 16% from 3Q 2019). Profit margin: 30% (up from 29% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Oct 13Square Pharmaceuticals Limited to Report Fiscal Year 2020 Results on Oct 22, 2020Square Pharmaceuticals Limited announced that they will report fiscal year 2020 results on Oct 22, 2020業績と収益の成長予測DSE:SQURPHARMA - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/2028105,00833,79224,40533,56836/30/202795,26330,69122,50430,01536/30/202685,11226,60016,94924,25633/31/202683,52725,86313,97922,300N/A12/31/202581,95225,94815,03221,629N/A9/30/202580,12825,28014,55520,543N/A6/30/202576,28823,96811,12517,302N/A3/31/202575,86023,5038,19313,723N/A12/31/202472,26622,3756,33013,124N/A9/30/202470,03721,0178,10513,518N/A6/30/202470,10120,92614,34818,529N/A3/31/202464,65120,23810,30314,192N/A12/31/202364,00419,59912,05213,911N/A9/30/202364,48919,4809,62011,800N/A6/30/202360,70818,9805,6858,546N/A3/31/202362,02018,8566,96810,289N/A12/31/202260,78219,1436,25210,594N/A9/30/202258,79118,6806,85912,222N/A6/30/202257,59818,1576,69212,875N/A3/31/202256,71318,5268,51414,936N/A12/31/202154,83417,8198,30714,183N/A9/30/202153,00417,0129,07013,949N/A6/30/202150,70315,9477,17810,976N/A3/31/202149,02114,4847,34410,544N/A12/31/202048,39514,2379,53212,249N/A9/30/202047,15813,9337,90310,427N/A6/30/202045,87613,3548,71810,760N/A3/31/202046,36013,73310,20312,019N/A12/31/201945,13813,236N/A11,586N/A9/30/201944,78512,831N/A12,455N/A6/30/201944,03412,646N/A12,392N/A3/31/201942,32212,168N/A10,525N/A12/31/201841,25212,025N/A9,288N/A9/30/201840,32811,754N/A9,493N/A6/30/201839,65411,594N/A9,905N/A3/31/201839,47411,667N/A9,371N/A12/31/201739,13111,622N/A10,071N/A9/30/201737,97811,222N/A9,723N/A6/30/201736,54310,637N/A9,542N/A3/31/201735,58410,330N/A9,806N/A12/31/201634,5349,893N/A9,348N/A9/30/201633,4489,639N/A10,637N/A6/30/201633,0749,199N/A9,615N/A12/31/201529,6427,770N/A9,487N/A9/30/201528,4007,091N/A8,298N/A6/30/201527,5316,411N/A7,223N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SQURPHARMAの予測収益成長率 (年間11.4% ) は 貯蓄率 ( 4.2% ) を上回っています。収益対市場: SQURPHARMAの収益 ( 11.4% ) BD市場 ( 15.1% ) よりも低い成長が予測されています。高成長収益: SQURPHARMAの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: SQURPHARMAの収益 ( 10.1% ) BD市場 ( 11% ) よりも低い成長が予測されています。高い収益成長: SQURPHARMAの収益 ( 10.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SQURPHARMAの 自己資本利益率 は、3年後には低くなると予測されています ( 18.2 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/28 12:36終値2026/05/24 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Square Pharmaceuticals PLC. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関S M Toufique ImranBRAC EPL Stock Brokerage LtdAsif KhanEDGE Research & ConsultingAnik Mahmood AnwarUCB Stock Brokerage Limited1 その他のアナリストを表示
Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.
Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.
Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.
Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Female Independent Director Nasrin Akter was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Square Pharmaceuticals PLC. to Report Q3, 2026 Results on Apr 29, 2026Square Pharmaceuticals PLC. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 25Square Pharmaceuticals PLC. to Report Q2, 2026 Results on Jan 29, 2026Square Pharmaceuticals PLC. announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 07Square Pharmaceuticals PLC. to Report Q1, 2026 Results on Nov 12, 2025Square Pharmaceuticals PLC. announced that they will report Q1, 2026 results on Nov 12, 2025
お知らせ • Oct 24Square Pharmaceuticals plc announces Annual dividend, payable on January 14, 2026Square Pharmaceuticals plc announced Annual dividend of BDT 12.0000 per share payable on January 14, 2026, ex-date on November 17, 2025 and record date on November 16, 2025.
お知らせ • Oct 23Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025Square Pharmaceuticals PLC., Annual General Meeting, Dec 15, 2025, at 10:00 Central Asia Standard Time.
お知らせ • Apr 23Square Pharmaceuticals PLC. to Report Q3, 2025 Results on Apr 29, 2025Square Pharmaceuticals PLC. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 27Square Pharmaceuticals PLC. to Report Q2, 2025 Results on Jan 30, 2025Square Pharmaceuticals PLC. announced that they will report Q2, 2025 results on Jan 30, 2025
Upcoming Dividend • Nov 17Upcoming dividend of ৳11.00 per shareEligible shareholders must have bought the stock before 24 November 2024. Payment date: 19 January 2025. Payout ratio is a comfortable 46% and the cash payout ratio is 94%. Trailing yield: 4.9%. Within top quartile of Bangladeshi dividend payers (4.3%). Higher than average of industry peers (3.6%).
New Risk • Nov 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Dividend is not well covered by cash flows (94% cash payout ratio).
お知らせ • Nov 08Square Pharmaceuticals PLC. to Report Q1, 2025 Results on Nov 14, 2024Square Pharmaceuticals PLC. announced that they will report Q1, 2025 results on Nov 14, 2024
Declared Dividend • Oct 26Dividend of ৳11.00 announcedShareholders will receive a dividend of ৳11.00. Ex-date: 24th November 2024 Payment date: 19th January 2025 Dividend yield will be 5.1%, which is higher than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (46% earnings payout ratio) but not adequately covered by cash flows (90.0% cash payout ratio). The dividend has increased by an average of 20% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 46% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Oct 24+ 1 more updateSquare Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024Square Pharmaceuticals PLC., Annual General Meeting, Dec 18, 2024, at 10:00 Central Asia Standard Time.
お知らせ • Oct 15Square Pharmaceuticals PLC. to Report Fiscal Year 2024 Results on Oct 23, 2024Square Pharmaceuticals PLC. announced that they will report fiscal year 2024 results on Oct 23, 2024
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳5.55 (vs ৳4.83 in 3Q 2023)Third quarter 2024 results: EPS: ৳5.55 (up from ৳4.83 in 3Q 2023). Revenue: ৳17.2b (up 8.4% from 3Q 2023). Net income: ৳4.92b (up 15% from 3Q 2023). Profit margin: 29% (up from 27% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Apr 26Square Pharmaceuticals PLC. to Report Q3, 2024 Results on Apr 29, 2024Square Pharmaceuticals PLC. announced that they will report Q3, 2024 results on Apr 29, 2024
Reported Earnings • Feb 02Second quarter 2024 earnings released: EPS: ৳5.92 (vs ৳5.78 in 2Q 2023)Second quarter 2024 results: EPS: ৳5.92 (up from ৳5.78 in 2Q 2023). Revenue: ৳18.5b (up 14% from 2Q 2023). Net income: ৳5.24b (up 2.3% from 2Q 2023). Profit margin: 28% (down from 32% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Jan 26Square Pharmaceuticals PLC. to Report Q2, 2024 Results on Jan 31, 2024Square Pharmaceuticals PLC. announced that they will report Q2, 2024 results on Jan 31, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 4 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Nov 12Upcoming dividend of ৳10.50 per share at 5.0% yieldEligible shareholders must have bought the stock before 19 November 2023. Payment date: 14 January 2024. Payout ratio is a comfortable 47% but the company is paying out more than the cash it is generating. Trailing yield: 5.0%. Within top quartile of Bangladeshi dividend payers (3.3%). Higher than average of industry peers (2.5%).
お知らせ • Oct 26Square Pharmaceuticals PLC. Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Square Pharmaceuticals PLC. has recommended 105% Cash Dividend for the year ended June 30, 2023.
お知らせ • Oct 24Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023Square Pharmaceuticals PLC., Annual General Meeting, Dec 14, 2023, at 10:00 Bangladesh Standard Time. Agenda: To consider 105% Cash Dividend for the year ended June 30, 2023.
お知らせ • Oct 13Square Pharmaceuticals PLC. to Report Fiscal Year 2023 Results on Oct 22, 2023Square Pharmaceuticals PLC. announced that they will report fiscal year 2023 results on Oct 22, 2023
Reported Earnings • May 04Third quarter 2023 earnings released: EPS: ৳4.83 (vs ৳5.15 in 3Q 2022)Third quarter 2023 results: EPS: ৳4.83 (down from ৳5.15 in 3Q 2022). Revenue: ৳15.9b (up 8.4% from 3Q 2022). Net income: ৳4.28b (down 6.3% from 3Q 2022). Profit margin: 27% (down from 31% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia.
Reported Earnings • Feb 01Second quarter 2023 earnings released: EPS: ৳5.78 (vs ৳5.24 in 2Q 2022)Second quarter 2023 results: EPS: ৳5.78 (up from ৳5.24 in 2Q 2022). Revenue: ৳16.2b (up 14% from 2Q 2022). Net income: ৳5.13b (up 10% from 2Q 2022). Profit margin: 32% (down from 33% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Nov 22Upcoming dividend of ৳10.00 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 23 January 2023. Payout ratio is a comfortable 29% and the cash payout ratio is 76%. Trailing yield: 4.8%. Within top quartile of Bangladeshi dividend payers (3.8%). Higher than average of industry peers (2.6%).
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ৳5.15 (vs ৳4.36 in 3Q 2021)Third quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 4 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Sep 01Price target increased to ৳348Up from ৳320, the current price target is an average from 3 analysts. New target price is 64% above last closing price of ৳212. Stock is down 7.7% over the past year. The company is forecast to post earnings per share of ৳20.46 for next year compared to ৳17.99 last year.
Reported Earnings • May 02Third quarter 2022 earnings: EPS exceeds analyst expectationsThird quarter 2022 results: EPS: ৳5.15 (up from ৳4.36 in 3Q 2021). Revenue: ৳14.7b (up 15% from 3Q 2021). Net income: ৳4.57b (up 18% from 3Q 2021). Profit margin: 31% (up from 30% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 12%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target increased to ৳314Up from ৳291, the current price target is an average from 6 analysts. New target price is 39% above last closing price of ৳226. Stock is up 7.0% over the past year. The company is forecast to post earnings per share of ৳20.19 for next year compared to ৳17.99 last year.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 2 independent directors (5 non-independent directors). Independent Director S. M. Rahman was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Price Target Changed • Feb 03Price target increased to ৳313Up from ৳276, the current price target is an average from 4 analysts. New target price is 38% above last closing price of ৳227. Stock is down 1.0% over the past year. The company is forecast to post earnings per share of ৳20.10 for next year compared to ৳17.99 last year.
Reported Earnings • Feb 03Second quarter 2022 earnings: EPS exceeds analyst expectationsSecond quarter 2022 results: EPS: ৳5.24 (up from ৳4.33 in 2Q 2021). Revenue: ৳14.2b (up 15% from 2Q 2021). Net income: ৳4.64b (up 21% from 2Q 2021). Profit margin: 33% (up from 31% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.5%. Over the next year, revenue is forecast to grow 11%, compared to a 21% growth forecast for the industry in Bangladesh. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 18Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).
Upcoming Dividend • Nov 16Upcoming dividend of ৳6.00 per shareEligible shareholders must have bought the stock before 23 November 2021. Payment date: 16 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.7%).
Reported Earnings • May 09Third quarter 2021 earnings released: EPS ৳4.36 (vs ৳4.08 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: ৳12.8b (up 5.2% from 3Q 2020). Net income: ৳3.86b (up 6.8% from 3Q 2020). Profit margin: 30% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 01Price target raised to ৳267Up from ৳245, the current price target is an average from 4 analysts. The new target price is 17% above the current share price of ৳228. As of last close, the stock is up 21% over the past year.
Reported Earnings • Feb 01Second quarter 2021 earnings released: EPS ৳4.33 (vs ৳3.98 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: ৳12.4b (up 11% from 2Q 2020). Net income: ৳3.84b (up 8.7% from 2Q 2020). Profit margin: 31% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 14New 90-day high: ৳238The company is up 22% from its price of ৳195 on 15 October 2020. The Bangladeshi market is up 16% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳119 per share.
Is New 90 Day High Low • Dec 21New 90-day high: ৳203The company is up 4.0% from its price of ৳196 on 22 September 2020. The Bangladeshi market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ৳150 per share.
Reported Earnings • Nov 17Third quarter 2020 earnings released: EPS ৳4.28The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳12.1b (up 11% from 3Q 2019). Net income: ৳3.62b (up 16% from 3Q 2019). Profit margin: 30% (up from 29% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Oct 13Square Pharmaceuticals Limited to Report Fiscal Year 2020 Results on Oct 22, 2020Square Pharmaceuticals Limited announced that they will report fiscal year 2020 results on Oct 22, 2020